

Agenda

MOC na ASCO 2023



CABEÇA e PESCOÇO

Lucas Vieira dos Santos



MOC na ASCO 2023

- Médico Oncologista Clínico do Centro de Oncologia da BP – a Beneficência Portuguesa de São Paulo, focado em tratamento das neoplasias de cabeça e pescoço e neoplasias gastrointestinais.

- CRM 115.834 SP.

Conflitos de Interesse



MOC na ASCO 2023

De acordo com a Norma 1595/2000 do Conselho Federal de Medicina e com a RDC 96/2008 da ANVISA, declaro:

- Apoio educacional: Bayer, BMS, Lilly, Merck, Merck KGaA, United Medical.
- Apoio para pesquisa: BMS, Exelixis, Merck, Roche.
- Consultoria: Merck, Roche, United Medical.

Como começar?



MOC na ASCO 2023

The screenshot shows the ASCO website interface for the 2023 Annual Meeting. The main navigation includes 'Meetings & Education', 'Research & Data', 'News & Initiatives', and 'Get Involved'. The user is logged in as 'Ld'. The page displays the '2023 ASCO Annual Meeting' details, including dates (June 2-6, 2023) and location (Chicago, IL). A 'Scheduled Sessions' filter overlay is active, showing a list of session types with checkboxes and counts:

- Education Session (83)
- Oral Abstract Session (25)
- Poster Discussion Session (24)
- Poster Session (24)
- Case-Based Panel (21)
- Clinical Science Symposium (14)
- Ticketed Session (13)
- Highlights of the Day Session (3)
- Rapid Abstract Session (3)
- Award Lecture (2)

An 'Apply' button is visible at the bottom of the filter overlay. The background shows search results for 'June 2, 2023' with 217 results, including a 'Workshop' and 'In-Person' session.



Oral abstract session

- Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.
Presenter: Lin-Quan Tang, PhD | Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy
Abstract: 6000
- Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.
Presenter: MingYuan Chen, MD&PhD | Sun Yat-sen University Cancer Center
Abstract: 6001



Oral abstract session

- PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).
Presenter: Jun Ma | Department of Radiation Oncology, Sun Yat-sen University Cancer Center
Abstract: LBA6002
- Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
Presenter: Jerome Fayette, MD, PhD | Centre Leon Bérard, Medical Oncology
Abstract: 6003



Oral abstract session

- Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.

Presenter: Ari Rosenberg, MD | University of Chicago

Abstract: 6007

Poster session

- Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC).

Presenter: Hyunwook Kim, MD | Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine

Abstract: 2578 - Poster Bd #: 420



Poster session

- Immune checkpoint inhibitor in high-risk oral potentially malignant disorders (IMPEDE study): An interim analysis on safety.
Presenter: Paolo Bossi | Medical Oncology Unit, Department of Medical & Surgical Specialties, Radiological Sciences & Public Health, University of Brescia, ASST Spedali Civili
Abstract: 2595 - Poster Bd #: 437
- DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab plus tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative head and neck squamous cell carcinoma (LA-HNSCC).
Presenter: Ulrich Keilholz, MD | Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Comprehensive Cancer Center
Abstract: 2611 - Poster Bd #: 453



Poster session

- Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.
Presenter: Heath Devin Skinner, MD, PhD | UPMC Hillman Cancer Center, Department of Radiation Oncology
Abstract: 6014 - Poster Bd #: 6
- Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
Presenter: Robert L. Ferris, MD, PhD | Hillman Cancer Center
Abstract: 6018 - Poster Bd #: 10

Créditos

MOC na ASCO 2023 © 2023 MOC - Manual de Oncologia Clínica do Brasil. Todos os direitos reservados. São Paulo, SP.
Proibida a reprodução total ou parcial do conteúdo e imagens sem a permissão dos titulares de seus direitos autorais.

Apoio educacional:

